Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of Veregen in actinic keratosis of the face and scalp
2022-502811-12-00Phase 3Authorised
- Sponsor
- Aresus Pharma
- Start
- Sep 2024
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing Veregen with Placebo (2 arms). Primary endpoint: Complete clinical clearance at end of interventional period. Planned start Sep 2024; status: authorised.
02
Drugs
sinecatechins
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2022-502811-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502811-12-00.